A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

OBJECTIVE: A randomized, placebo-controlled, double-blind, multicenter 52-week phase 2 trial of resveratrol in individuals with mild to moderate Alzheimer disease (AD) examined its safety and tolerability and effects on biomarker (plasma Aβ40 and Aβ42, CSF Aβ40, Aβ42, tau, and phospho-tau 181) and v...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurology
Main Authors: Turner, R. Scott, Thomas, Ronald G., Craft, Suzanne, van Dyck, Christopher H., Mintzer, Jacobo, Reynolds, Brigid A., Brewer, James B., Rissman, Robert A., Raman, Rema, Aisen, Paul S.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4626244/
https://ncbi.nlm.nih.gov/pubmed/26362286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000002035
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados